Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
15 studies found for:    CT-011
Show Display Options
RSS Create an RSS feed from your search for:
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
Condition: Lymphoma
Interventions: Drug: CT-011;   Drug: Rituximab
2 Completed Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Drug: CT-011
3 Completed Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone
Condition: Metastatic Colorectal Cancer
Interventions: Drug: CT-011;   Drug: FOLFOX
4 Terminated Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
Condition: Chronic Hepatitis C
Intervention: Drug: CT-011
5 Terminated Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
Condition: Primary Hepatocellular Carcinoma
Intervention: Drug: CT-011
6 Completed
Has Results
CT-011 MAb in DLBCL Patients Following ASCT
Conditions: Lymphoma, Large Cell, Diffuse;   Lymphoma, Mixed Cell, Diffuse;   Primary Mediastinal Large B-Cell Lymphoma
Intervention: Drug: CT-011
7 Suspended Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: CT-011 (Anti-PD1 Antibody);   Other: Sipuleucel-T (Provenge);   Drug: Cyclophosphamide
8 Suspended Gemcitabine and CT-011 for Resected Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Cancer of the Pancreas;   Neoplasms Pancreatic;   Pancreatic Cancer;   Pancreas Cancer
Interventions: Biological: CT-011;   Drug: Gemcitabine
9 Active, not recruiting Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Drug: CT-011;   Biological: Dendritic Cell Fusion Vaccine
10 Withdrawn CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
Conditions: Breast Cancer;   Colon Cancer;   Pancreatic Cancer;   Sarcoma;   Ovarian Cancer
Interventions: Biological: p53: 264-272 peptide;   Drug: CT-011
11 Active, not recruiting PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
Condition: Renal Cell Carcinoma
Interventions: Drug: CT-011;   Biological: DC/RCC fusion vaccine
12 Recruiting Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide;   Biological: pidilizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis
13 Recruiting Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission
Conditions: Stage III Diffuse Large B-Cell Lymphoma;   Stage IV Diffuse Large B-Cell Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pidilizumab
14 Recruiting Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission
Conditions: Acute Myelogenous Leukemia;   AML
Intervention: Biological: DC AML Vaccine
15 Completed Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal
Condition: Diabetes Mellitus Type 1
Interventions: Drug: BioChaperone insulin lispro;   Drug: Humalog®

Indicates status has not been verified in more than two years